Melinta Therapeutics

Melinta Therapeutics is an antibiotics-focused company. The company’s mission is to discover, develop and commercialize urgently needed, groundbreaking antibiotics to overcome drug-resistant, life-threatening infections.

The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI). In addition, Melinta is focused on its ongoing research program to develop a new class of antibiotics designed to overcome the resistant ESKAPE pathogens known to cause the majority of serious hospital infections and patient deaths. Melinta Therapeutics is privately held and backed by Vatera Healthcare Partners and Warburg Pincus.

Melinta Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Emergency Medicine sector. The company focuses on Biotechnology and has secured $196.5B in funding across 224 round(s). With a team of 101-250 employees, Melinta Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series D - Melinta Therapeutics, raised $25.0M. Discover more about their projects, partnerships, and impact on our platform.